BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CX Institutional | 13 | $5,000 | 0.00% |
| FEDERATED HERMES, INC. | 350 | $121,000 | 0.00% |
| Financial Management Professionals, Inc. | 3 | $1,000 | 0.00% |
| SIMPLEX TRADING, LLC | 117 | $40,000 | 0.00% |
| MASSMUTUAL TRUST CO FSB/ADV | 7 | $2,000 | 0.00% |
| JFS WEALTH ADVISORS, LLC | 7 | $2,000 | 0.00% |
| Blue Trust, Inc. | 9 | $4,000 | 0.00% |
| Capital Advisors, Ltd. LLC | 3 | $1,000 | 0.00% |
| Prestige Wealth Management Group LLC | 1 | $0 | 0.00% |
| Vigilant Capital Management, LLC | 12 | $4,000 | 0.00% |
| Morton Brown Family Wealth, LLC | 1 | $0 | 0.00% |
| Allworth Financial LP | 43 | $15,000 | 0.00% |
| Steward Financial Group LLC | 1 | $0 | 0.00% |
| Psagot Value Holdings Ltd. / (Israel) | 3 | $1,000 | 0.00% |
| EARNEST PARTNERS LLC | 4 | $1,000 | 0.00% |
| HM PAYSON & CO | 26 | $9,000 | 0.00% |
| LONGFELLOW INVESTMENT MANAGEMENT CO LLC | 2 | $1,000 | 0.00% |
| EVOKE WEALTH, LLC | 5 | $2,000 | 0.00% |
| Bogart Wealth, LLC | 0 | $0 | 0.00% |
| JONES FINANCIAL COMPANIES LLLP | 2 | $1,000 | 0.00% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.